Study of the Population of Enterochromaffin-Like Cells in Mouse Gastric Mucosa after Long-Term Treatment with Ebrotidine

Toxicologic Pathology

Volumn 24, Issue 2, 1996, Pages 160-165

  Romero, Alfonso ^a   Gómez, Francisca ^b   Villamayor, Frederic ^b   Sacristán, Aurelio ^b   Ortiz, José Alfonso ^b  

^a Department of Toxicology ^*  (Spain)

^b Ferrer Group   (Spain)

Author keywords

gastric acid secretion inhibitors; Hyperplasia

Indexed keywords

EBROTIDINE;

ANIMAL MODEL; ANIMAL TISSUE; ARGENTAFFIN CELL; ARTICLE; CELL DENSITY; CELL HYPERPLASIA; CELL POPULATION; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; ENTEROCHROMAFFIN CELL; FEMALE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SILVER STAINING; STOMACH ANTRUM; STOMACH FUNDUS; STOMACH MUCOSA;

ANIMALS; BENZENESULFONATES; CELL COUNT; CELL DIVISION; ENTEROCHROMAFFIN CELLS; FEMALE; GASTRIC MUCOSA; HISTAMINE H2 ANTAGONISTS; HYPERPLASIA; MALE; MICE; SEX CHARACTERISTICS; THIAZOLES;

ANIMALIA;

EID: 0029869508     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400203     Document Type: Article

References (32)

1. Anglada L., Marquez M., sacristán A., and Urtiz JA (1988). Inhibitors of gastric acid secretion. N-sulphonyl formamidines in a series of new histamine H2-receptor antagonists. Eur. J. Med. Chem. 23: 97-100.
2. Axelson J., Håkanson R., Rosengren E., and Sundler F. (1988). Hypergastrinemia induced by acid blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissue Res. 254: 511-516.
3. Betton GR, Dormer CHS, Wells T., Pert P., Pricce CA, and Buckley P. (1988). Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SKF 93479 and oxmetidine and omeprazole. Toxicol. Pathol. 16(2): 288-298.
4. Brittain RT, Jack D., Reeves JJ, and Stables R. (1985). Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. Br. J. Pharmacol. 85: 843-847.
5. Capella C. (1980). Gastric carcinoids of argyrophil ECL cells. Ultrastruct. Pathol. 1: 411-418.
6. Carlsson E., Havu N., Mattsson H., and Ekmon L. (1990). Gastric and gastric enterochromaffin-like cell carcinoids in the rat. Digestion 47(suppl.1): 17-23.
7. Consejo de las Comunidades Europeas (1986). Lineas Directrices relativas al alojamiento y a los cuidados de los animales. Anexo II al Artículo 5 de la Directiva del Consejo de 24 de Noviembre de 1986 respecto a la protección de los animales utilizados para experimentación y otros fines científicos (86/609/CEE). Diario Oficial Comunidad. Eur. 18.12.86, L358: 1-28.
8. Ekman L., Hansson E., Havu N., Carlsson E., and Lundberg C. (1985). Toxicological studies on omeprazole. Scand. J. Gastroenterol. 20(108): 53-69.
9. Falcó J., Romero A., Villamayor F., Sacristan A., and Ortiz JA (1992). Caracterización de células enteroendocrinas de la mucosa gástrica de roedor. In: II Simposio de la Sociedad Española de Ciencias del Animal de Laboratorio (SECAL). Programa y Resúmenes. Bellaterra, Barcelona, Spain.
10. Grimelius L. and Wilander E. (1980). Silver stains in the study of endocrine cells of the gut and pancreas. Invest. Cell Pathol. 3: 3-12.
11. Håkanson R. and Sunder F. (1986). Gastric carcinoids and antisecretory drugs. Trends Pharmacol. Sci. 7(10): 386-387.
12. Harvey RF, Bradshaw MJ, Davidson CM, Wilkinson SP, and Davies PS (1985). Multifocal gastric carcinoid tumours, achlorhydria, and hypergastrinemia. Lancet i: 951-953.
13. Havu N., Mattsson H., Ekman L., and Carlsson E. (1990). Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45: 189-195.
14. Hirth RS, Evans LD, Buroker RA, and Oleson FB (1988). Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: An indirect effect of the histamine H2-receptor antagonist, BL-6341. Toxicol. Pathol. 16(2): 273-287.
15. Konturek SJ, Brzowski T., Drozdowicz D., and Majka J. (1991). Ebrotidine a novel H2-receptor antagonist with local gastroprotective activity. Eur. J. Gastroenterol. Hepatol. 3(12): 941-947.
16. Larsson H., Carlsson E., Mattsson H., Lundell L., Sundler F., Sundler G., Wallmark B., Watanabe T., and Håkanson R. (1986). Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90: 391-399.
17. Lee Hong, Håkanson R., Karlsson A., Mattsson H., and Sundler F. (1992). Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastric cells and somatostatin cells in the rat stomach. Digestion 52: 125-132.
18. Maczka M., Kniecien N., Obtulowicz W., Konturek SS, Kaminski K., Olesky J., Gabryelenicz A., and Torres J. (1992). Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans. J. Physiol. Pharmacol. 43: 2.
19. Norušis MJ (1990). SPSS/PC+(™) 4.0 Base Manual for the IBM PC/XT/AT and PS/2. SPSS, Chicago.
20. Norušis MJ (1990). SPSS/PC+ Statistics(™) 4.0 for the IBM PC/XT/AT and PS/2. SPSS, Chicago.
21. Palop D., Conejo L., Sacristan A., and Ortiz JA (1994). Role of nitric oxide in gastroprotective effect of ebrotidine. Comparative study with carbenoxolone. Can. J. Physiol. Pharmacol. 72(suppl. 1): 238.
22. Palop D., Romero A., Villamayor F., Sacristan A., and Ortiz JA (1993). Effect of ebrotidine against gastric mucosal injury induced by ethanol in rats. Comparative study with other H2 receptor antagonists. In: II United European Gastroenterology Week Programme, Barcelona, Spain.
23. Penston J. (1987). Achlorhydria: Hypergastrinemia: Carcinoids-A flawed hypothesis? Gut 28: 488-505.
24. Poynter D., Pick CR, Harcourt RA, Selway SAM, Ainge G., Harwan IW, Spurling NW, Fluck PA, and Cook JL (1985). Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 26: 1284-1295.
25. Poynter D., Selway SAM, Papworth SA, and Riches SR (1986). Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut 27: 1338-1346.
26. Romero A., Rives A., Grau MT, Villamayor F., Sacristan A., and Ortiz JA (1993). Carcinogenicity studies of ebrotidine in mice. Eurotox '93, Uppsala, Sweden.
27. Ryberg B., Bishop AE, Bloom SR, Carlsson E., Håkanson R., Larsson H., Mattsson H., Polak JM, and Sundler F. (1989). Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplastic of enterochromaffin-like cells in rat stomach. Regul. Pept. 25: 235-246.
28. Slomiany BL, Piotrowski J., Mojtahed H., and Slomiany A. (1992). Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori. Gen. Pharmacol. 23(2): 203-206.
29. Slomiany BL, Piotrowski J., Murty VLN, and Slomiany A. (1992). Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol. Gen. Pharmacol. 23(4): 719-727.
30. Street CS, Cimprich RE, and Roberston JL (1984). Pathologic findings in the stomachs of rats treated with the H2-receptor antagonist tiotidine. Scand. J. Gastroenterol. 19(101): 109-117.
31. Street CS, Roberston JL, and Crissman JW (1988). Morphologic stomach findings in rats and mice treated with the H2 receptor antagonists, ICI 125, 211 and ICI 162, 846. Toxicol. Pathol. 16(2): 299-304.
32. Wallmark B., Skånberg I., Mattsson H., Andersson K., Sundler F., Håkanson R., and Carlsson E. (1990). Effect of 20 weeks ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat. Digestion 45: 181-188.